The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
2.
The Action to Control Cardiovascular Risk in Diabetes Study Group: Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
3.
AhmadiSS, WestmanK, PivodicA, et al.: The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: a randomized clinical trial (GOLD-4). Diabetes Care, 2020; 43:2017–2024.
4.
MonnierL, WojtusciszynA, MolinariN, et al.: Respective contributions of glycemic variability and mean daily glucose as predictors of hypoglycemia in type 1 diabetes: are they equivalent?. Diabetes Care, 2020; 43:821–827.
5.
MonnierL, ColetteC, WojtusciszynA, et al.: Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care, 2017; 40:832–838.
6.
DanneT, NimriR, BattelinoT, et al.: International consensus on use of continuous glucose monitoring. Diabetes Care, 2017; 40:1633–1640.
7.
BattelinoT, DanneT, BergenstalRM, et al.: Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42:1593–1603.
8.
UemuraF, OkadaY, MitaT, et al.: Risk factor analysis for type 2 diabetic patients about hypoglycemia using continuous glucose monitoring: results from a prospective observational study. Diabetes Technol Ther, 2022; 24:435–445.
9.
BergenstalRM, BeckRW, CloseKL, et al.: Glucose management indicator (GMI): a new term for estimating A1c from continuous glucose monitoring. Diabetes Care, 2018; 41:2275–2280.
10.
MazzeRS, StrockE, WesleyD, et al.: Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther, 2008; 10:149–159.
11.
HillNR, OliverNS, ChoudharyP, et al.: Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther, 2011; 13:921–928.
12.
SalkindSJ, HuizengaR, FondaSJ, et al.: Glycemic variability in non diabetic morbidity obese persons: results from an observational study and review of literature. J Diabetes Sci Technol, 2014; 8:1042–1047.
13.
ShahVN, DuBoseSN, LiZ, et al.: Continuous glucose monitoring profiles in healthy non-diabetic participants: a multicenter prospective study. J Clin Endocrinol Metab, 2019; 104:4356–4364.
14.
MonnierL, WojtusciszynA, ColetteC, et al.: The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther, 2011; 13:813–818.
15.
RodbardD: Hypo-and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther, 2012; 10:868–876.
16.
RodbardD: Glucose time in range, time above range, and time below range depend on mean or median glucose or HbA1c, glucose coefficient of variation, and shape of the glucose distribution. Diabetes Technol Ther, 2020; 22:492–500.
